Research ExplorerPublicationsCharacterization and Outcomes of Spanish Patients With Relap...

Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study

Standard

Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study. / Mateos, Maria-Victoria; Weisel, Katja; Diels, Joris; Arribas, Alberto; Tamayo, Maria; Schecter, Jordan M; Roccia, Tito; Haddad, Imène; Pacaud, Lida; Moreau, Philippe.

In: CL LYMPH MYELOM LEUK, Vol. 24, No. 4, 04.2024, p. 224-231.e2.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mateos, M-V, Weisel, K, Diels, J, Arribas, A, Tamayo, M, Schecter, JM, Roccia, T, Haddad, I, Pacaud, L & Moreau, P 2024, 'Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study', CL LYMPH MYELOM LEUK, vol. 24, no. 4, pp. 224-231.e2. https://doi.org/10.1016/j.clml.2023.12.001

APA

Mateos, M-V., Weisel, K., Diels, J., Arribas, A., Tamayo, M., Schecter, J. M., Roccia, T., Haddad, I., Pacaud, L., & Moreau, P. (2024). Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study. CL LYMPH MYELOM LEUK, 24(4), 224-231.e2. https://doi.org/10.1016/j.clml.2023.12.001

Vancouver

Mateos M-V, Weisel K, Diels J, Arribas A, Tamayo M, Schecter JM et al. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study. CL LYMPH MYELOM LEUK. 2024 Apr;24(4):224-231.e2. https://doi.org/10.1016/j.clml.2023.12.001

Bibtex

@article{5985d72a56094e698855a16e517ccd9f,
title = "Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study",
abstract = "BACKGROUND: Despite advances in treatments for multiple myeloma (MM), most patients relapse and become refractory to standard drug classes including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies. The LocoMMotion study showed poor clinical outcomes in triple-class exposed patients with relapsed/refractory MM (RRMM) treated with real-world clinical practice (RWCP) therapy. Here, we report efficacy outcomes for Spanish patients receiving RWCP treatments in the LocoMMotion study compared with the full cohort.PATIENTS AND METHODS: The prospective, noninterventional, multinational LocoMMotion study (NCT04035226) enrolled 248 patients who had received ≥ 3 prior lines of therapy (LOT), including a PI, an IMiD, and an anti-CD38 antibody, with disease progression during or after their last LOT. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS) and overall survival (OS).RESULTS: Spanish patients (n = 24) had received a median of 4 prior LOT (range, 2-7). At 29.2 months median follow-up, patients had received 14 different treatment regimens used in RWCP during the study. Efficacy outcomes were consistent between the Spanish cohort and overall study population. The ORR was 29.2% (95% CI, 12.6%-51.1%). Median PFS and OS were 4.6 months (95% CI, 1.2-6.3) and 11.6 months (95% CI, 6.4-24.5), respectively.CONCLUSION: Spanish patients from the LocoMMotion study demonstrated poor outcomes in response to RWCP treatments consistent with those of the overall study population, highlighting the need for access to new and effective therapies for patients with RRMM in Spain and globally.",
author = "Maria-Victoria Mateos and Katja Weisel and Joris Diels and Alberto Arribas and Maria Tamayo and Schecter, {Jordan M} and Tito Roccia and Im{\`e}ne Haddad and Lida Pacaud and Philippe Moreau",
note = "Copyright {\textcopyright} 2023. Published by Elsevier Inc.",
year = "2024",
month = apr,
doi = "10.1016/j.clml.2023.12.001",
language = "English",
volume = "24",
pages = "224--231.e2",
journal = "CL LYMPH MYELOM LEUK",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "4",

}

RIS

TY - JOUR

T1 - Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study

AU - Mateos, Maria-Victoria

AU - Weisel, Katja

AU - Diels, Joris

AU - Arribas, Alberto

AU - Tamayo, Maria

AU - Schecter, Jordan M

AU - Roccia, Tito

AU - Haddad, Imène

AU - Pacaud, Lida

AU - Moreau, Philippe

N1 - Copyright © 2023. Published by Elsevier Inc.

PY - 2024/4

Y1 - 2024/4

N2 - BACKGROUND: Despite advances in treatments for multiple myeloma (MM), most patients relapse and become refractory to standard drug classes including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies. The LocoMMotion study showed poor clinical outcomes in triple-class exposed patients with relapsed/refractory MM (RRMM) treated with real-world clinical practice (RWCP) therapy. Here, we report efficacy outcomes for Spanish patients receiving RWCP treatments in the LocoMMotion study compared with the full cohort.PATIENTS AND METHODS: The prospective, noninterventional, multinational LocoMMotion study (NCT04035226) enrolled 248 patients who had received ≥ 3 prior lines of therapy (LOT), including a PI, an IMiD, and an anti-CD38 antibody, with disease progression during or after their last LOT. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS) and overall survival (OS).RESULTS: Spanish patients (n = 24) had received a median of 4 prior LOT (range, 2-7). At 29.2 months median follow-up, patients had received 14 different treatment regimens used in RWCP during the study. Efficacy outcomes were consistent between the Spanish cohort and overall study population. The ORR was 29.2% (95% CI, 12.6%-51.1%). Median PFS and OS were 4.6 months (95% CI, 1.2-6.3) and 11.6 months (95% CI, 6.4-24.5), respectively.CONCLUSION: Spanish patients from the LocoMMotion study demonstrated poor outcomes in response to RWCP treatments consistent with those of the overall study population, highlighting the need for access to new and effective therapies for patients with RRMM in Spain and globally.

AB - BACKGROUND: Despite advances in treatments for multiple myeloma (MM), most patients relapse and become refractory to standard drug classes including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies. The LocoMMotion study showed poor clinical outcomes in triple-class exposed patients with relapsed/refractory MM (RRMM) treated with real-world clinical practice (RWCP) therapy. Here, we report efficacy outcomes for Spanish patients receiving RWCP treatments in the LocoMMotion study compared with the full cohort.PATIENTS AND METHODS: The prospective, noninterventional, multinational LocoMMotion study (NCT04035226) enrolled 248 patients who had received ≥ 3 prior lines of therapy (LOT), including a PI, an IMiD, and an anti-CD38 antibody, with disease progression during or after their last LOT. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS) and overall survival (OS).RESULTS: Spanish patients (n = 24) had received a median of 4 prior LOT (range, 2-7). At 29.2 months median follow-up, patients had received 14 different treatment regimens used in RWCP during the study. Efficacy outcomes were consistent between the Spanish cohort and overall study population. The ORR was 29.2% (95% CI, 12.6%-51.1%). Median PFS and OS were 4.6 months (95% CI, 1.2-6.3) and 11.6 months (95% CI, 6.4-24.5), respectively.CONCLUSION: Spanish patients from the LocoMMotion study demonstrated poor outcomes in response to RWCP treatments consistent with those of the overall study population, highlighting the need for access to new and effective therapies for patients with RRMM in Spain and globally.

U2 - 10.1016/j.clml.2023.12.001

DO - 10.1016/j.clml.2023.12.001

M3 - SCORING: Journal article

C2 - 38212206

VL - 24

SP - 224-231.e2

JO - CL LYMPH MYELOM LEUK

JF - CL LYMPH MYELOM LEUK

SN - 2152-2650

IS - 4

ER -